Description: BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California.
Home Page: www.bioatla.com
BCAB Technical Analysis
11085 Torreyana Road
San Diego,
CA
92121
United States
Phone:
858 558 0708
Officers
| Name | Title |
|---|---|
| Dr. Jay M. Short Ph.D. | Co-Founder, CEO & Chairman |
| Mr. Scott Andrew Smith | Pres & Director |
| Mr. Richard A. Waldron | Chief Financial Officer |
| Dr. Eric L. Sievers M.D. | Chief Medical Officer |
| Mr. Christian Vasquez | VP of Fin., Corp. Controller & Sec. |
| Mr. Philippe Martin | Chief Clinical Devel. & Operations |
| Lisa M. Pelton | Accounting Mang. |
| Ms. Susie Melody | Sr. VP of HR |
| Dr. Cathy Chang Ph.D. | Sr. VP of R&D |
| Ms. Monica Sullivan | Sr. VP of Intellectual Property & Contracts |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.5839 |
| Price-to-Sales TTM: | 989.2236 |
| IPO Date: | 2020-12-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 56 |